J. Wiltfang

发表

Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease

J. Wiltfang, B. Mollenhauer, H. Kretzschmar, 2005, Journal of Neural Transmission.

Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies

M. Neumann, H. A. Kretzschmar, J. Wiltfang, 2000, Neurology.

Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial

W. Maier, I. Heuser, J. Kornhuber, 2018, The Journal of Prevention of Alzheimer's Disease.

Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.

L. Minthon, K. Blennow, H. Zetterberg, 2009, The Journal of Nutrition, Health & Aging.

Creutzfeldt–Jakob disease and oxidative stress

J. Kornhuber, J. Wiltfang, H. Kretzschmar, 2000, Acta neurologica Scandinavica.

Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies

J. Wiltfang, W. Schulz-Schaeffer, H. Kretzschmar, 2000, Neurology.

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease

J. Wiltfang, B. Mollenhauer, H. Kretzschmar, 2002, Neurology.

Specific 14-3-3 isoform detection and immunolocalization in prion diseases.

J. Wiltfang, H. Baxter, A. Aitken, 2001, Biochemical Society transactions.

Isoform Pattern of 14‐3‐3 Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt‐Jakob Disease

J. Kornhuber, J. Wiltfang, H. Kretzschmar, 1999, Journal of neurochemistry.

Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study

O. Gefeller, A. Giese, H. Kretzschmar, 1998, BMJ.

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

P. Cupers, E. Rüther, J. Wiltfang, 2001, The Journal of biological chemistry.